2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
To test an acellular dermal template (Novomaix) in human patients in need of full thickness skin defect coverage and to compare the results with those obtained after conventional STSG. The main goals are to study the efficacy and scar quality after…